5,147 Shares in Sanofi (NASDAQ:SNY) Acquired by Net Worth Advisory Group

Net Worth Advisory Group bought a new position in shares of Sanofi (NASDAQ:SNY) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 5,147 shares of the company’s stock, valued at approximately $297,000.

Several other hedge funds have also recently added to or reduced their stakes in the business. Dynamic Advisor Solutions LLC lifted its stake in Sanofi by 39.2% during the first quarter. Dynamic Advisor Solutions LLC now owns 57,204 shares of the company’s stock valued at $2,780,000 after buying an additional 16,117 shares in the last quarter. Manning & Napier Advisors LLC acquired a new position in Sanofi in the 2nd quarter worth approximately $13,725,000. Mount Yale Investment Advisors LLC boosted its stake in Sanofi by 44.3% in the 1st quarter. Mount Yale Investment Advisors LLC now owns 41,707 shares of the company’s stock worth $2,027,000 after purchasing an additional 12,806 shares during the period. Jennison Associates LLC grew its position in Sanofi by 18.9% during the 1st quarter. Jennison Associates LLC now owns 189,622 shares of the company’s stock worth $9,216,000 after purchasing an additional 30,115 shares in the last quarter. Finally, Sei Investments Co. lifted its holdings in shares of Sanofi by 9.3% in the first quarter. Sei Investments Co. now owns 554,028 shares of the company’s stock valued at $26,926,000 after purchasing an additional 47,297 shares in the last quarter. Institutional investors and hedge funds own 10.04% of the company’s stock.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on SNY. Argus upped their price target on Sanofi from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Friday, July 26th. StockNews.com downgraded Sanofi from a “strong-buy” rating to a “buy” rating in a report on Monday, October 14th. Finally, Citigroup upgraded shares of Sanofi to a “strong-buy” rating in a report on Tuesday, September 17th. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi presently has a consensus rating of “Moderate Buy” and a consensus target price of $57.50.

Sanofi Stock Up 0.1 %

Shares of Sanofi stock opened at $54.93 on Monday. The firm has a market cap of $139.12 billion, a price-to-earnings ratio of 27.60, a P/E/G ratio of 1.57 and a beta of 0.60. The stock has a 50-day simple moving average of $56.11 and a 200-day simple moving average of $51.58. Sanofi has a 52-week low of $42.63 and a 52-week high of $58.97. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.00 and a quick ratio of 0.65.

Sanofi (NASDAQ:SNY) last posted its earnings results on Thursday, July 25th. The company reported $0.93 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.05. Sanofi had a net margin of 9.60% and a return on equity of 26.29%. The firm had revenue of $10.75 billion during the quarter, compared to analysts’ expectations of $16.86 billion. During the same period in the previous year, the company earned $0.95 earnings per share. The company’s revenue was up 7.8% compared to the same quarter last year. On average, equities research analysts expect that Sanofi will post 4.26 earnings per share for the current fiscal year.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.